Vor Biopharma Inc. VOR
Updated: 9 Aug 2026
No signal published yet
We already track Vor Biopharma and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Vor Biopharma Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Vor Biopharma free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 3, 2026, Vor Bio announced equity inducement grants under Nasdaq Listing Rule 5635(c)(4). In June 2026, its lead candidate telitacicept received regulatory approval from China's NMPA for the treatment of Sjögren's disease. The company is currently advancing global Phase 3 registrational trials for the drug candidate.
What Firelda Watch includes for Vor Biopharma Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Vor Biopharma Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Vor Biopharma free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more